Highlights,Tectonic Advisors LLC increased its position in Gilead Sciences, Inc. by 15.1% during the third ...

The Ministry of Health and Welfare announced that health insurance for Paxlovid Jung of Pfizer Pharmaceutical Korea and Veclurizu of Gilead Sciences Korea ...

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00. The ...

The Biden administration on Oct. 21 issued a new proposed rule that would require health insurance providers to cover an ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation ...

With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give ...

FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.

On CGEN's third-quarter 2024 earnings call, investors' focus is likely to be on updates on its pipeline candidates being studied for cancer immunotherapies.

Counsel from Pfizer, Gilead, and Bristol Myers Squibb spoke on AI’s transformative power and risks, reports Marisa Woutersen ...